 |  |  |  |  |
|---|
Headquartered in North Bethesda, Maryland, Ibex Biosciences, Inc. ("Ibex") distinguishes itself in the early-stage biotech sector with its varied research and development approach.
Ibex is committed to discovering, validating, and developing potential health solutions through investment in unconventional projects and methodologies, irrespective of their recognition within the broader research community.
Ibex has an open Regulation D 506(c) offering
Research & Development
Ibex boasts a diverse portfolio that includes therapeutic antibodies, gene therapies, and regenerative medicine programs.
We are proud of our proven capacity to discover and validate potential therapies from scratch, thus eliminating the need for external technology acquisitions or in-licensing.
Our accomplishments are underscored by a series of in-vivo studies, which have delivered remarkable efficacy against a range of challenging medical conditions.
Highlights
Ibex Announces New Patent Pending
Ibex announces the patent publication of Antibodies targeted to CD147, including ADC🎥
Ibex Biosciences awarded as a Top 10 Biotech Startup
Ibex recognized as an Innovative Biotech Company